After outshining the standard of care for yeast infections in a midstage trial, Scynexis’ broad-spectrum antifungal has delivered again. The drug beat placebo at clearing up vulvovaginal candidiasis in a second phase 3 study, teeing up an FDA submission in the second half of 2020.